Juno Archives -

Cancer/ Market Access/ News/ News/ News/ Oncology

Bluebird bio details plans to file three blockbusters

Richard Staines blood cancer, bluebird bird, cancer, Gilead, Juno, Novartis 0 Comment

Biotech looks to take on Novartis, Gilead, and Juno in CAR-T

Bluebird bio details plans to file three blockbusters

https://pharmaphorum.com/news/bluebird-bio-aims/

News/ News/ Oncology/ R&D/ Top stories

Celgene in talks to buy CAR-T partner Juno

Andrew McConaghie CAR T, Celgene, Juno 0 Comment

Celgene is understood to be in talks to buy CAR-T specialists Juno Therapeutics, in a deal which could

Celgene in talks to buy CAR-T partner Juno

https://pharmaphorum.com/news/celgene-talks-buy-car-t-partner-juno/

News/ News/ Oncology/ R&D/ US

Cellectis gets FDA go-ahead to restart fatal CAR-T trial

Richard Staines cancer, CAR T, Cellectis, Gilead, Juno, Novartis, R&D, safety 0 Comment

Regulator agrees to restart phase 1 trial of UCART 123

Cellectis gets FDA go-ahead to restart fatal CAR-T trial

https://pharmaphorum.com/news/cellectis-gets-fda-go-ahead-restart-fatal-car-t-trial/

T-cells attacking cancer cell illustration of microscopic photos

News/ News/ Oncology/ R&D/ Top stories

Juno bounces back with ‘best in class’ CAR-T

Richard Staines blood cancer, CAR T, Gilead, Juno, Novartis 0 Comment

Juno has hopes pinned on JCAR017

Juno bounces back with ‘best in class’ CAR-T

https://pharmaphorum.com/news/new-car-t-revive-struggling-juno/

News/ R&D/ US

Juno boosted by CAR-T trial findings in NHL

Richard Staines blood cancer, cancer, CAR T, Juno, Kite Pharma, non-Hodgkin lymphoma, Novartis 0 Comment

Biotech plans pivotal trial next year.

Juno boosted by CAR-T trial findings in NHL

https://pharmaphorum.com/news/juno-boosted-car-t-trial-findings-nhl/

News/ Novartis/ US

Kite in CAR-T pole position as rolling submission begins

Richard Staines blood cancer, bluebirdbio, cancer, CAR T, Juno, Kite Pharma, Novartis 0 Comment

Kite to start filing data for KTE-C19 with US regulator.

Kite in CAR-T pole position as rolling submission begins

https://pharmaphorum.com/news/kite-says-on-track-for-2017-car-t-therapy-launch/

News/ R&D

Juno halts CAR-T trial again after 2 more deaths

Richard Staines cancer, cancer immunotherapy, Juno, Kite Pharma, Novartis, R&D, safety 0 Comment

Doubts over Juno CAR-T therapy after two more trial deaths.

Juno halts CAR-T trial again after 2 more deaths

https://pharmaphorum.com/news/juno-car/

Cancer/ News/ UK & Europe

Adaptimmune revives ovarian cancer trial

Richard Staines Adaptimmune, cancer, immuno-oncology, Juno, Kite, T-cell 0 Comment

T-cell trial will include controversial chemo agent fludarabine.

Adaptimmune revives ovarian cancer trial

https://pharmaphorum.com/news/adaptimmune-revives-ovarian-cancer-trial/

Articles/ Cancer/ R&D/ Views and analysis

Novartis committed to CAR-Ts – but doubts about commercial viability remain

Richard Staines cancer, Cancer Research Technology, CAR T, immunotherapy, Juno, Kite, Novartis, Oncology 0 Comment

Novartis may have concerns about commercial prospects, says expert.

Novartis committed to CAR-Ts – but doubts about commercial viability remain

https://pharmaphorum.com/views-and-analysis/will-car-t-profitable-pharma/

Trending

Juno

Login